GSK
GSK
774 hedge funds and large institutions have $11.3B invested in GSK in 2021 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 300 increasing their positions, 292 reducing their positions, and 89 closing their positions.
31% more call options, than puts
Call options by funds: $152M | Put options by funds: $116M
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
3% more repeat investments, than reductions
Existing positions increased: 300 | Existing positions reduced: 292
2% more capital invested
Capital invested by funds: $11.1B → $11.3B (+$205M)
0.22% more ownership
Funds ownership: 4.81% → 5.04% (+0.22%)
5% less funds holding
Funds holding: 818 → 774 (-44)
39% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$908M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$255M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$124M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$82.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$200M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$199M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$180M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$164M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.3M |
GSK Hedge Fund Activity: Q1 2021 in Review
774 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2021, worth a combined $11.3B — up 1.8% from $11.1B a quarter earlier.
Sellers outnumbered buyers: 89 funds closed out of GSK and 54 opened new positions — a net loss of 35 holders — while 292 trimmed existing stakes and 300 added.
The largest buyer was Dodge & Cox, adding an estimated $908M. The largest seller was Renaissance Technologies, cutting an estimated $200M.
- 774 institutional investors held GSK (GSK) as of Q1 2021, down from 818 in Q4 2020.
- Funds reported $11.3B of GSK stock for Q1 2021, up 1.8% quarter-over-quarter.
- 54 funds opened new GSK positions in Q1 2021 and 89 closed out, a net change of -35 holders.
- The largest GSK buyer in Q1 2021 was Dodge & Cox, an estimated $908M added.
- The largest GSK seller in Q1 2021 was Renaissance Technologies, an estimated $200M sold.
Based on aggregated 13F filings for Q1 2021.